Skip to content

Synthetic cell biomimics cancer to avoid transplant rejection.

For people dealing with the life-changing and often devastating aftermath of disfiguring injuries or the loss of limbs, minimal reconstruction using the patients’ own tissues may not be a sufficient remedy for some patients. Face and limb transplantation, known as Vascularized Composite Allotransplantation (VCA), requires multiple types of tissue to successfully function, these may include skin, muscle, nerves, and blood vessels. As with organ transplantation, VCA also necessitates the use of drugs, known as immunosuppressants, to stop the host immune system rejecting the foreign transplant tissue, a regimen that lasts for life. However, immunosuppressive drugs cause a host of adverse events. Now, a study from researchers at the University of Pittsburgh engineers artificial microparticles that trick the recipient’s immune system into accepting donor transplanted tissue as its own. The team states their synthetic particle biomimics the ploy cancer cells use to evade an immune attack, to propagate and spread. The opensource study is published in the journal Science Advances.

Previous studies show transplant patients are required to take immunosuppressant drugs for life, which weaken the immune system raising the risk of a host of infectious diseases, as well as cancer and diabetes. Therefore, an alternative approach to achieving graft acceptance through recruiting the body’s own immune system without compromising it is highly sort after. A promising hypothesis involves regulatory T cells (Treg) which are important in the regulation of immunological homeostasis. Certain tumors are known to recruit Treg cells via the release of the protein CCL22 to hide from the immune system, a property that would benefit CVA. The current study develops a synthetic microparticle system that biomimics this strategy to recruit Treg cells to use the CCL22 protein to avoid transplant rejection.

The current study engineers an artificial, controlled-release microparticle that is also fully-degradable, and capable of generating and sustaining a gradient of CCL22 ‘tumor protein’. Results show when the artificial microparticles release the CCL22 protein, the Treg cells are naturally drawn to the site of the transplantation where they tag the foreign tissue as self so it is accepted by the immune system. Data findings show the animal transplant models that had the microparticles injected twice annually maintained healthy grafts within the timeframe they were monitored, which was approximately a year.

The lab states the murine transplant models that were treated with the microparticles exhibited permanent immune tolerance to grafts, including a whole limb from a donor rat, whilst maintaining immunological homeostasis. They go on the add the ability to induce transplant acceptance without suppressing the immune system could be important in regards to VCA where patients transplants are needed to improve quality-of-life.

The team surmises they have engineered a synthetic biomimetic system that enables the cloaking and acceptance of complex VCA without compromising the immune system. For the future, the researchers state their artificial microparticle platform could have broader applications in inflammatory or autoimmune disorders where current treatments carry serious risks.

Source: University of Pittsburgh

Get Healthinnovations delivered to your inbox:

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio,, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.